Analysts Set Cognition Therapeutics, Inc. (NASDAQ:CGTX) PT at $3.33

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been assigned a consensus recommendation of “Moderate Buy” from the four analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $3.3333.

CGTX has been the topic of several recent research reports. Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of Cognition Therapeutics in a report on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Friday, March 27th. Finally, raised Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd.

Cognition Therapeutics Trading Up 0.8%

CGTX stock opened at $1.26 on Friday. The firm has a market cap of $112.77 million, a P/E ratio of -5.25 and a beta of 1.81. Cognition Therapeutics has a 12-month low of $0.22 and a 12-month high of $3.83. The stock’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.28.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, research analysts forecast that Cognition Therapeutics will post -0.32 EPS for the current fiscal year.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. lifted its holdings in shares of Cognition Therapeutics by 34.7% in the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after purchasing an additional 7,641 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in Cognition Therapeutics by 69.1% during the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after acquiring an additional 16,129 shares in the last quarter. Jones Financial Companies Lllp bought a new stake in Cognition Therapeutics during the 3rd quarter valued at $25,000. Essex Financial Services Inc. raised its stake in Cognition Therapeutics by 100.0% during the 1st quarter. Essex Financial Services Inc. now owns 40,000 shares of the company’s stock valued at $30,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in Cognition Therapeutics during the 3rd quarter valued at $27,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.